Summit Therapeutics Inc. ("Summit," "we," or the "Company") today announced that Robert LaCaze has joined Summit Therapeutics as Chief Commercial Officer, reporting to Manmeet S. Soni, Chief Operating ...

Glargine U300 use was common, especially with increased CKD stages and baseline HbA1c levels among patients with type 2 diabetes.

Maxim analyst Naz Rahman lowered the firm’s price target on scPharmaceuticals (SCPH) to $12 from $20 but keeps a Buy rating on the shares after ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

The National Kidney Foundation (NKF) is proud to announce that its KidneyCARE (Community Access to Research Equity)™ Study – ...

Increased antibiotic use can lead, seemingly paradoxically, to more problematic infections, as the bacteria evolve to resist ...

SeaStar Medical (Nasdaq: ICU) has been selected to receive the 2025 Corporate Innovator Award from the National Kidney ...

Bayer has claimed EU approval for Kerendia, its new drug for chronic kidney disease (CKD) in people with type 2 diabetes, as the company tries to build a role of the drug alongside rival therapies ...

Q4 2024 Management View CEO John Tucker highlighted FUROSCIX's Q4 2024 net revenue of $12.2 million, which aligns with the previously announced range of $12 million to $12.3 million. For the full year ...

Artificial intelligence (AI) is reshaping the pharmaceutical industry, driving advances from drug discovery and clinical trial acceleration to manufacturing optimisation and commercialisation.

Perform material- and labor-effective extrusion with Thermo Scientific™ Pharma 11 Twin-screw Extruder, which requires only a small amount of active pharmaceutical ingredient, operating at ...